Reveromycin A

• UNSPSC Description:

  Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity[1][2].

• Target Antigen:

  Antibiotic; Apoptosis; Fungal

• Type:

  Natural Products

• Related Pathways:

  Anti-infection;Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/reveromycin-a.html

• Purity:

  99.00

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(O[C@@]1(CCCC)[C@H](/C=C/C(C)=C/C(O)=O)O[C@]2(O[C@H](C/C=C(C)/C=C/[C@H](O)[C@@H](C)/C=C/C(O)=O)[C@@H](C)CC2)CC1)CCC(O)=O

• Molecular Weight:

  660.79

• References & Citations:

  [1]H Takahashi , et al. Reveromycins, new inhibitors of eukaryotic cell growth. II. Biological activities. J Antibiot (Tokyo). 1992 Sep;45(9):1414-9.|[2]Je-Tae Woo, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4729-34.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  134615-37-5